Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening

Description

The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.

Conditions

Anal Dysplasia

Talk to us

Study Overview

On this page

Study Details

Study overview

The study is to test a liquid biopsy assay for screening and classifying anal dysplasia from blood.

Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening

Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening

Condition
Anal Dysplasia
Intervention / Treatment

-

Contacts and Locations

Boston

Department of Infectious Diseases, Mass General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Past or current anal HPV-positive population undergone anal dysplasia screening.
  • * Control patients from the general population.
  • * Not meeting inclusion criteria.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Massachusetts Eye and Ear Infirmary,

Daniel L. Faden, M.D., PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2025-07